CClinicalTrials.gg
RecruitingNCT07038486Updated Jan 8, 2026

Patient Engagement Investigation of NMS Assist

An interventional study of NMS Assist in Parkinson Disease, sponsored by Newcastle University. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Newcastle University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Parkinson's can cause a wide range of non-motor symptoms (NMS), including pain and problems with mental health, memory and sleep. These affect the quality of life of people with Parkinson's (PwP) and their care partners (CP). If these issues are not recognised and managed quickly, they can result in escalating problems. Many PwP are unsure of the extent and variety of the NMS and how simple adjustments at home could improve them. We have developed a digital system to help PwP monitor their non-motor symptoms and develop skills to self-manage them.

Such a tool needs to be simple to use, safe and effective. We will ask 30 PwP and CPs to use the digital tool for 6 months, and we will monitor how they use the tool. PwP and CPs will be asked if they feel more knowledgeable and confident to manage their own symptoms whilst being better able to discuss a problem with their healthcare professional.

A smaller group of participants will discuss their experiences in more detail to help pinpoint aspects that work well and those needing adjustment and development.

It is thought that the use of this system will result in improved quality of life and increased knowledge and confidence for managing symptoms while safely reducing the time spent by healthcare professionals on manageable non-motor symptoms.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson disease
  • Self-management
  • mhealth
  • mobile apps
  • telemedicine
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Individuals will be eligible if they meet the following inclusion criteria:

All:

  • Age 18 years or over
  • Have compatible smartphone/data access (access to a digital device is a necessary prerequisite of system use, and the formative usability study had success in recruiting participants with varying levels of experience with smartphones)
  • Be fluent in English
  • Able and willing to provide informed consent
  • Able and willing to comply with intervention requirements

For clinically diagnosed people with Parkinson's (PwP) (ICD-10-CM G20):

  • Not resident in a care home or nursing home
  • Ambulant
  • Interested in monitoring and managing their NMS

For CPs:

- Be caring for a clinically diagnosed PwP (ICD-10-CM G20) who is participating in the study

Exclusion Criteria: Participants will be ineligible for the study if they meet any of the following exclusion criteria:

All:

  • Previous involvement in the development or testing of the digital system
  • In a dependent/unequal relationship with the research or care teams or any PPI representatives

PwP:

  • Secondary cause of Parkinsonism
  • Significant cognitive impairment or a diagnosis of Parkinson's disease dementia
  • Significant comorbidity, which, in the opinion of the chief investigator, would preclude safe participation in the study or protocol compliance
  • A life expectancy of \<6 months
  • Living in residential care facilities
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    NMS Assist

    NMS Assist provides a system of linking PwP, CPs, and healthcare providers (HCPs) to monitor and empower self-management of non-motor symptoms through the use of a mobile app and web portal.

    Device: NMS Assist

Interventions

  • DeviceNMS Assist

    The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.

05

What researchers measure

Primary outcomes

  1. Feasibility of the intervention

    The primary outcome will be assessed using a composite of variables: recruitment, retention, system uptime, adherence/engagement, technical issues, and a review of the health and well-being outcomes (secondary outcomes). Adherence/engagement will be measured using system use data (trend of use over time). This will be supplemented with semi-structured interviews and a user engagement questionnaire to gain a better understanding of users' experience engaging with the intervention and the recommended behaviours. Technical issues will be identified through system use data (including logs of complaints made by participants during the intervention delivery period) as well as asking participants about any technical issues encountered during the semistructured interviews. Product complaints will be collected through feedback recorded via the platform, collected at study assessment points or manually provided via email throughout the study duration.

    Time frame: Assessed throughout the 6-month study duration

Secondary outcomes

  1. Presence of non-motor symptoms

    Measured using the Non-Motor Symptoms Questionnaire (NMSQ), patients tick 'yes' or 'no' for each symptom listed

    Time frame: Measured monthly for 6 months

  2. Patient (and care partner) activation

    Patient Activation Measure (and caregiver version) will be used to evaluate their confidence, knowledge, and skills at non-motor symptom self-management

    Time frame: Assessed monthly for 6 months

  3. Frequency and severity of non-motor symptoms

    Measured using the Movement Disorder Society Non-Motor Symptoms Scale (MDS-NMS), where higher scores indicate greater frequency and/or severity

    Time frame: Measured at baseline, 3, and 6 months

  4. Long-form self-assessment of functioning and well-being related to Parkinson's disease

    Measured using the long-form Parkinson's Disease Questionnaire PDQ-39, patients indicate the frequency with which they experience certain issues

    Time frame: Measured at baseline, 3, and 6 months

  5. Short-form self-assessment of functioning and well-being related to Parkinson's disease

    Measured using the short-form Parkinson's Disease Questionnaire (PDQ-8), patients indicate the frequency with which they experience certain issues

    Time frame: Measured monthly for 6 months

  6. Carer well-being and quality of life

    Measured using the Parkinson Disease Questionnaire for care partners; care partners indicate the frequency with which they experience certain issues

    Time frame: Measured monthly for 6 months

  7. Health status

    Measured using the EQ-5D-5L; higher scores on the EQ-5D-5L descriptive system indicate worse health problems in the specific dimension whereas a high score in the EQ VAS indicates better health on the day of the questionnaire

    Time frame: Measured at baseline, 3, and 6 months

  8. Adverse events

    Adverse event reporting

    Time frame: Throughout the 6-month study period

  9. Healthcare contacts

    Number of PwP-initiated contacts with healthcare team (through the 'request healthcare contact' feature) recorded by the system

    Time frame: Throughout the 6-month study period

  10. Quantitative usability

    Using the mHealth app usability questionnaire (MAUQ) with higher scores indicating better usability

    Time frame: 3 and 6 months

  11. Acceptability

    Acceptability and usability feedback from semi-structured interviews

    Time frame: 3 and 6 months

  12. Costs will be conducted, in conjunction with an adaptation of Client Service Receipt Inventory (CSRI)

    Cost analysis will be conducted, in conjunction with an adaptation of Client Service Receipt Inventory (CSRI) for Parkinson's disease. The scale will be administered at 3 and 6 months.

    Time frame: Throughout 6 months

06

Study locations

1 of 1 sites recruiting
  • Newcastle University
    Newcastle upon Tyne, Tyne and Wear NE4 8EA, United Kingdom
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided — Data belongs to the study sponsor (Newcastle University) and deidentified data will be made available in line with the data sharing policy developed with Parkinson's UK and PPI representatives.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07038486
Lead sponsor
Newcastle University
Responsible party
Edward Meinert (Professor of Digital Health and Clinical Artificial Intelligence, Newcastle University) — Principal investigator
First posted
Jun 26, 2025
Start date
Aug 6, 2025
Primary completion
Sep 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion